Eva Holtved
Impact in
Papers in
- Co-authors
- Yuichiro� Doki (10 shared papers)Yuko Kitagawa (10 shared papers)Chih‐Hung Hsu (10 shared papers)Ioannis Xynos (6 shared papers)Myung‐Ju Ahn (4 shared papers)Masanobu Takahashi (5 shared papers)Shigenori Kadowaki (5 shared papers)Yasuo Hamamoto (5 shared papers)
In The Last Decade
Eva Holtved
17 papers receiving 1.1k citations
Eva Holtved's Hit Papers
Peers
Comparison fields: 5 of 63
- Oncology 466
- Surgery 472
- Pulmonary and Respiratory Medicine 271
- Cancer Research 80
- Radiation 39
Countries citing papers authored by Eva Holtved
This map shows the geographic impact of Eva Holtved's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Eva Holtved with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Eva Holtved more than expected).
Fields of papers citing papers by Eva Holtved
This network shows the impact of papers produced by Eva Holtved. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Eva Holtved. The network helps show where Eva Holtved may publish in the future.
Co-authors
The 25 scholars most cited alongside Eva Holtved, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial Hit paper breakdown → | 2019 | 786 |
| 2 | 2021 | 62 | |
| 3 | 2020 | 55 | |
| 4 | 2015 | 41 | |
| 5 | 2017 | 33 | |
| 6 | Three-year follow-up and response-survival relationship of nivolumab in previously treated patients with advanced esophageal squamous cell carcinoma (ATTRACTION-3) | 2022 | 28 |
| 7 | 2019 | 12 | |
| 8 | 2016 | 12 | |
| 9 | 2021 | 9 | |
| 10 | 2023 | 8 | |
| 11 | Hypoxia-regulated MicroRNAs in Gastroesophageal Cancer. | 2016 | 7 |
| 12 | 2022 | 6 | |
| 13 | 2016 | 6 | |
| 14 | 2020 | 5 | |
| 15 | 2022 | 5 | |
| 16 | 2024 | 1 | |
| 17 | Nivolumab versus Chemotherapy in Advanced Esophageal Squamous Cell Carcinoma (ESCC): The Phase 3 attraction-3 Study | 2020 | 1 |
| 18 | 2024 | 0 | |
| 19 | 2024 | 0 | |
| 20 | 2025 | 0 |
About Eva Holtved
Eva Holtved is a scholar working on Surgery, Oncology, Pulmonary and Respiratory Medicine, Radiation and Gastroenterology, having authored 20 papers that have together received 1.1k indexed citations. Recurring topics across this work include Esophageal Cancer Research and Treatment (14 papers), Cancer Immunotherapy and Biomarkers (12 papers), Pancreatic and Hepatic Oncology Research (3 papers), Gastric Cancer Management and Outcomes (3 papers), CAR-T cell therapy research (2 papers), Health Systems, Economic Evaluations, Quality of Life (1 paper), Gastrointestinal Tumor Research and Treatment (1 paper) and Cancer Genomics and Diagnostics (1 paper). The work is most often cited by research in Oncology (466 citations), Surgery (472 citations), Pulmonary and Respiratory Medicine (271 citations), Cancer Research (80 citations) and Radiation (39 citations). Eva Holtved has collaborated with scholars based in Denmark, Japan and Taiwan. Frequent co-authors include Yuichiro� Doki, Yuko Kitagawa, Chih‐Hung Hsu, Ioannis Xynos, Myung‐Ju Ahn, Masanobu Takahashi, Shigenori Kadowaki, Yasuo Hamamoto, Sung‐Bae Kim and Yutaro Kubota. Their work appears in journals such as Journal of Clinical Oncology, Acta Oncologica, Annals of Oncology, European Spine Journal and The Lancet Oncology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.